BioNexus Gene Lab Corp. (BGLC)
USD 2.67
(-2.2%)
USD 2.67
(-2.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.59 Million USD | -790.73% |
| 2022 | -291.17 Thousand USD | -127.58% |
| 2021 | 1.05 Million USD | -17.11% |
| 2020 | 1.27 Million USD | 562.02% |
| 2019 | -275.7 Thousand USD | -560.27% |
| 2018 | 59.9 Thousand USD | 146.83% |
| 2017 | -127.91 Thousand USD | -15127.38% |
| 2016 | -840.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -470.94 Thousand USD | 192.27% |
| 2024 Q1 | -280.88 Thousand USD | -209.42% |
| 2023 Q3 | -2.52 Million USD | -828.54% |
| 2023 FY | -2.59 Million USD | -790.73% |
| 2023 Q2 | -272.19 Thousand USD | -437.61% |
| 2023 Q1 | -50.63 Thousand USD | 58.73% |
| 2023 Q4 | 256.7 Thousand USD | 110.16% |
| 2022 FY | -291.17 Thousand USD | -127.58% |
| 2022 Q4 | -122.68 Thousand USD | -88.13% |
| 2022 Q3 | -65.21 Thousand USD | 52.73% |
| 2022 Q2 | -137.96 Thousand USD | -497.69% |
| 2022 Q1 | 34.69 Thousand USD | -82.75% |
| 2021 Q2 | 139.99 Thousand USD | -59.08% |
| 2021 FY | 1.05 Million USD | -17.11% |
| 2021 Q1 | 342.1 Thousand USD | -76.35% |
| 2021 Q4 | 201.06 Thousand USD | -46.04% |
| 2021 Q3 | 372.64 Thousand USD | 166.19% |
| 2020 Q4 | 1.44 Million USD | 2529.35% |
| 2020 Q2 | -66.05 Thousand USD | -40.25% |
| 2020 FY | 1.27 Million USD | 562.02% |
| 2020 Q3 | -59.54 Thousand USD | 9.85% |
| 2020 Q1 | -47.09 Thousand USD | 51.02% |
| 2019 FY | -275.7 Thousand USD | -560.27% |
| 2019 Q1 | -60.2 Thousand USD | 15.93% |
| 2019 Q4 | -96.14 Thousand USD | -91.76% |
| 2019 Q3 | -50.13 Thousand USD | 27.57% |
| 2019 Q2 | -69.21 Thousand USD | -14.98% |
| 2018 Q1 | -49.11 Thousand USD | 19.49% |
| 2018 FY | 59.9 Thousand USD | 146.83% |
| 2018 Q4 | -71.61 Thousand USD | -29.87% |
| 2018 Q3 | -55.14 Thousand USD | -39.7% |
| 2018 Q2 | -39.47 Thousand USD | 19.64% |
| 2017 Q4 | -61.01 Thousand USD | 0.0% |
| 2017 FY | -127.91 Thousand USD | -15127.38% |
| 2016 FY | -840.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 97.336% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 76.321% |
| Aspira Women's Health Inc. | -18.85 Million USD | 86.242% |
| Biodesix, Inc. | -41.34 Million USD | 93.727% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 67.471% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 67.471% |
| Bionano Genomics, Inc. | -215.24 Million USD | 98.795% |
| CareDx, Inc | -101.9 Million USD | 97.455% |
| Check-Cap Ltd. | -19.28 Million USD | 86.553% |
| Castle Biosciences, Inc. | -67.97 Million USD | 96.185% |
| DarioHealth Corp. | -56.18 Million USD | 95.384% |
| Exact Sciences Corporation | -215.01 Million USD | 98.794% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 96.432% |
| Guardant Health, Inc. | -564.72 Million USD | 99.541% |
| ICON Public Limited Company | 956.15 Million USD | 100.271% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.236% |
| Illumina, Inc. | -1.06 Billion USD | 99.757% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 74.778% |
| iSpecimen Inc. | -11.16 Million USD | 76.779% |
| Standard BioTools Inc. | -76.6 Million USD | 96.614% |
| MDxHealth SA | -27.32 Million USD | 90.509% |
| 23andMe Holding Co. | -321.35 Million USD | 99.193% |
| Medpace Holdings, Inc. | 336.82 Million USD | 100.77% |
| Myriad Genetics, Inc. | -123.7 Million USD | 97.903% |
| Mainz Biomed B.V. | -26.64 Million USD | 90.266% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 75.348% |
| NeoGenomics, Inc. | -107.73 Million USD | 97.593% |
| Neogen Corporation | 58.66 Million USD | 104.421% |
| Inotiv, Inc. | -81.46 Million USD | 96.816% |
| Natera, Inc. | -446.24 Million USD | 99.419% |
| OpGen, Inc. | -15.68 Million USD | 83.468% |
| OPKO Health, Inc. | -157.02 Million USD | 98.348% |
| Psychemedics Corporation | -2.92 Million USD | 11.209% |
| Prenetics Global Limited | -52.51 Million USD | 95.061% |
| Prenetics Global Limited | -52.51 Million USD | 95.061% |
| Precipio, Inc. | -7.62 Million USD | 65.963% |
| Personalis, Inc. | -109.93 Million USD | 97.641% |
| RadNet, Inc. | 98.69 Million USD | 102.628% |
| Sera Prognostics, Inc. | -39.82 Million USD | 93.487% |
| Sotera Health Company | 276.69 Million USD | 100.937% |
| Neuronetics, Inc. | -30.55 Million USD | 91.511% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 40.322% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 40.322% |
| Trinity Biotech plc | -27.04 Million USD | 90.41% |
| T2 Biosystems, Inc. | -49.66 Million USD | 94.778% |
| Twist Bioscience Corporation | -220.83 Million USD | 98.826% |
| Exagen Inc. | -22.83 Million USD | 88.643% |